Geller Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$3.01M Sell
3,895
-131
-3% -$108K 0.2% 32
2024
Q3
$3.57M Sell
4,026
-363
-8% -$326K 0.25% 28
2024
Q2
$3.97M Buy
4,389
+196
+5% +$157K 0.29% 24
2024
Q1
$3.26M Buy
4,193
+301
+8% +$214K 0.26% 27
2023
Q4
$2.27M Sell
3,892
-11
-0.3% -$6.42K 0.22% 30
2023
Q3
$2.1M Buy
3,903
+668
+21% +$344K 0.24% 27
2023
Q2
$1.52M Buy
3,235
+424
+15% +$178K 0.19% 31
2023
Q1
$965K Buy
2,811
+535
+24% +$180K 0.14% 32
2022
Q4
$833K Sell
2,276
-348
-13% -$123K 0.14% 35
2022
Q3
$848K Buy
2,624
+386
+17% +$122K 0.18% 25
2022
Q2
$726K Sell
2,238
-8
-0.4% -$2.4K 0.15% 37
2022
Q1
$643K Buy
2,246
+10
+0.4% +$2.57K 0.12% 48
2021
Q4
$618K Buy
2,236
+71
+3% +$18K 0.12% 49
2021
Q3
$500K Sell
2,165
-96
-4% -$23.7K 0.11% 56
2021
Q2
$519K Sell
2,261
-98
-4% -$19.7K 0.11% 52
2021
Q1
$441K Buy
2,359
+727
+45% +$142K 0.1% 55
2020
Q4
$390K Hold
1,632
0.1% 57
2020
Q3
$242K Sell
1,632
-105
-6% -$16.3K 0.07% 70
2020
Q2
$285K Buy
+1,737
New +$267K 0.09% 59

Other funds holding LLY

Geller Advisors's LLY Position: Q4 2024 in Review

Geller Advisors reduced its Eli Lilly (LLY) stake by 3.3% in Q4 2024, selling an estimated $108K and leaving 3,895 shares worth $3.01M. The position accounts for 0.2% of the portfolio, ranked #32.

Geller Advisors first reported a position in LLY in Q2 2020 and has held it in 19 quarters since. The position peaked at $3.97M in Q2 2024. 3,906 funds tracked by Wall St. Rank hold LLY as of Q4 2024.

  • Geller Advisors held 3,895 shares of Eli Lilly worth $3.01M as of Q4 2024.
  • Geller Advisors sold 131 Eli Lilly shares in Q4 2024, an estimated $108K.
  • Eli Lilly made up 0.2% of Geller Advisors's portfolio in Q4 2024, its #32 holding.
  • Geller Advisors first reported a position in Eli Lilly in Q2 2020 and has held it in 19 quarters since.
  • Geller Advisors's Eli Lilly position peaked at $3.97M in Q2 2024.
  • 3,906 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2024.

Based on Geller Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.